Insiders Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Market Closed - Nasdaq Other stock markets 21:00:00 10/05/2024 BST			5-day change	1st Jan Change
25.96 ^USD	-4.21%		-1.85%	+186.85%

05-09	Avidity Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05-08	Avidity Biosciences Receives FDA Breakthrough Therapy Designation for Treatment of Myotonic Dystrophy Type 1	MT

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Avidity Biosciences Insider Sold Shares Worth $734,919, According to a Recent SEC Filing	04-04	MT
Avidity Biosciences Insider Sold Shares Worth $542,214, According to a Recent SEC Filing	04-04	MT
Avidity Biosciences Insider Sold Shares Worth $980,760, According to a Recent SEC Filing	03-15	MT
Avidity Biosciences Insider Sold Shares Worth $609,017, According to a Recent SEC Filing	03-13	MT
Avidity Biosciences Insider Sold Shares Worth $1,691,306, According to a Recent SEC Filing	03-05	MT
Avidity Biosciences Appoints Strategy Chief, Plans to Start Phase 3 Myotonic Dystrophy Type 1 Study	01-05	MT
Avidity Biosciences, Inc. Announces Resignation of Eric Mosbrooker as Board of Directors and the Human Capital Management Committee of the Board	01-05	CI
Avidity Biosciences, Inc. Announces Executive Changes	24/02/23	CI
Avidity Biosciences, Inc. Announces Changes to Its Board	23/02/23	CI
Insider Sell: Avidity Biosciences	03/02/23	MT
Insider Sell: Avidity Biosciences	03/01/23	MT
Avidity Biosciences, Inc Appoints Michael MacLean as Chief Business Officer	05/04/22	CI
Avidity Biosciences, Inc. Appoints Steve Hughes, M.D., as Chief Medical Officer	23/02/22	CI
Design Therapeutics Names Jae Kim as Chief Medical Officer	02/02/22	MT
Avidity Biosciences, Inc. Announces Resignation of Joseph Baroldi as Chief Operating Officer, Effective January 22, 2022	06/01/22	CI
Avidity Biosciences : Shares Slide After Chief Medical Officer Steps Down	01/09/21	MT
Avidity Biosciences, Inc. Announces Executive Changes	01/09/21	CI
Avidity Biosciences, Inc. Announces Board Changes	25/08/21	CI
Avidity Biosciences Appoints W. Michael Flanagan as Chief Technical Officer	21/01/21	CI
Avidity Biosciences, Inc. Announces Management Changes	11/01/21	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Insiders Avidity Biosciences, Inc.

Equities

RNA

US05370A1088

Insiders

Filters